Jul. 24 at 10:39 AM
$SLS while I am looking forward to Dr. Stergiou’s appearance this morning I am keeping it in perspective. While he is free to talk about SLS009 and in general about GPS, the quiet period will bar him from discussing details of Regal.
In other words do not tune in expecting he is going to tell you about Regal topline data. That’s not happening. That will be done 2 to 3 weeks after you receive the press release of the 80th event.
I do expect he will talk all about SLS 009 and how incredible it is and how incredible the potential is for GPS.
If you want to day trade
$SLS then this is a significant appearance.
Otherwise, the only thing that REALLY matters are the Regal top line results. That could send the price of
$SLS up 5 to 10 times if results are great and the company gets bought out by big pharma (likely
$MRK or
$JNJ).
If they’re not great, the stock could go to three dollars to five dollars. Everything else is noise. Everything.
The top line data from Regal is everything in this kind of stock.
The REALLY good news is last night’s massive AML study that was published by, among others, the head of the Regal steering committee, strongly supports the argument that it is GPS - not BAT - keeping 38 percent of the Regal patients alive for so long.
First of all when reviewing the survival times from that study, they are artificially long compared to Regal because that study measured survival times from the beginning of induction treatment, not the beginning of CR1. Regal measures survival from the beginning of CR2.
And once you account for that and then reduce the survival times of CR1 commensurately to the MUCH shorter survival times in CR2 it’s very clear that we are looking at no more than 6 to 12 months (and more likely 6 to 10 months) for BAT median overall survival which would make Regal a smashing success for GPS given how long 38 percent of the Regal cohort lives.
Not financial advice. Do your own due diligence. Good luck to all the longs.
